Zytiga

DRUG3 trials

Sponsors

Bayer, Tavanta Therapeutics, Bukwang Pharmaceutical

Conditions

Metastatic Castration-resistant Prostate CancerMetastatic Castration-sensitive Prostate CancerMetastatic Prostate CancerProstate CancerProstatic Neoplasms, Castration-Resistant

Phase 1

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

CompletedNCT06014853

Bukwang PharmaceuticalProstate Cancer

Start: 2023-08-10End: 2023-11-16Updated: 2024-02-05

Phase 3

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

CompletedNCT04887506

Tavanta TherapeuticsMetastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer

Start: 2021-05-05End: 2022-10-20Updated: 2024-01-16

Unknown Phase

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

WithdrawnNCT03325127

BayerProstatic Neoplasms, Castration-Resistant

Start: 2017-10-30End: 2018-09-28Updated: 2018-10-31

Related Papers

A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial.

Journal of Clinical Oncology2023-06-011 citations